{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"OtherAbstract": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "SpaceFlightMission": [], "KeywordList": [], "InvestigatorList": [], "PMID": "7902181", "DateCompleted": {"Year": "1993", "Month": "12", "Day": "28"}, "DateRevised": {"Year": "2019", "Month": "05", "Day": "12"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0007-1188", "JournalIssue": {"Volume": "110", "Issue": "2", "PubDate": {"Year": "1993", "Month": "Oct"}}, "Title": "British journal of pharmacology", "ISOAbbreviation": "Br J Pharmacol"}, "ArticleTitle": "Pharmacological activity of (-)-discretamine, a novel vascular alpha-adrenoceptor and 5-hydroxytryptamine receptor antagonist, isolated from Fissistigma glaucescens.", "Pagination": {"StartPage": "882", "EndPage": "888", "MedlinePgn": "882-8"}, "Abstract": {"AbstractText": ["1. The pharmacological activity of (-)-discretamine, isolated from Fissistigma glaucescens, was determined in rat isolated thoracic aorta, cardiac tissues and ventricular myocytes and guinea-pig isolated trachea. 2. (-)-Discretamine was found to be an alpha 1-adrenoceptor blocking agent in rat thoracic aorta as revealed by its competitive antagonism of noradrenaline (pA2 = 7.20 +/- 0.10)- or phenylephrine (pA2 = 7.60 +/- 0.09)-induced vasoconstriction. It was as potent as phentolamine (pA2 = 7.51 +/- 0.10), but was more potent than yohimbine (pA2 = 6.18 +/- 0.06). Removal of endothelium significantly increased the antagonistic potency of (-)-discretamine on noradrenaline (pA2 = 7.52 +/- 0.09)- or phenylephrine (pA2 = 7.90 +/- 0.09)-induced vasoconstriction. 3. (-)-Discretamine was also an alpha 2-adrenoceptor blocking agent (pA2 = 6.30 +/- 0.15) and a 5-hydroxytryptamine antagonist (pA2 = 6.87 +/- 0.06), both in rat aorta denuded of endothelium. 4. (-)-Discretamine protected alpha-adrenoceptors from alkylation by the irreversible blocking agent, phenoxybenzamine. 5. [3H]-inositol monophosphate formation caused by noradrenaline (3 microM) in rat thoracic aorta was suppressed by (-)-discretamine (10 and 30 microM) and prazosin (3 microM). 6. A high concentration of (-)-discretamine (30 microM) did not affect the contraction induced by the thromboxane receptor agonist U-46619, prostaglandin F2 alpha (PGF2 alpha), angiotensin II, high K+ or endothelin in rat aorta denuded of endothelium. Neither cyclic AMP nor cyclic GMP content of rat thoracic aorta was changed by (-)-discretamine. 7. Contraction of guinea-pig trachea caused by histamine, leukotriene C4 or carbachol was not affected by (-)-discretamine (30 microM). (-)-Discretamine also did not block beta l- or beta2-adrenoceptor-mediated responses induced by isoprenaline in rat right atria and guinea-pig trachea.8. A voltage clamp study in rat ventricular single myocytes revealed that sodium inward current, slow inward Ca2+ current or transient (ItO) and steady state (I800) outward current was not affected by(-)-discretamine (30 microM).9. It is concluded that (-)-discretamine is a selective x-adrenoceptor and 5-HT receptor antagonist in vascular smooth muscle."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacological Institute, College of Medicine, National Taiwan University, Taipei."}], "LastName": "Ko", "ForeName": "F N", "Initials": "FN"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Yu", "ForeName": "S M", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Su", "ForeName": "M J", "Initials": "MJ"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Wu", "ForeName": "Y C", "Initials": "YC"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Teng", "ForeName": "C M", "Initials": "CM"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Br J Pharmacol", "NlmUniqueID": "7502536", "ISSNLinking": "0007-1188"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Adrenergic alpha-Antagonists"}, {"RegistryNumber": "0", "NameOfSubstance": "Adrenergic beta-1 Receptor Antagonists"}, {"RegistryNumber": "0", "NameOfSubstance": "Berberine Alkaloids"}, {"RegistryNumber": "0", "NameOfSubstance": "Cytokines"}, {"RegistryNumber": "0", "NameOfSubstance": "Potassium Channels"}, {"RegistryNumber": "0", "NameOfSubstance": "Serotonin Antagonists"}, {"RegistryNumber": "0", "NameOfSubstance": "Sodium Channels"}, {"RegistryNumber": "4L6452S749", "NameOfSubstance": "Inositol"}, {"RegistryNumber": "605-34-5", "NameOfSubstance": "discretamine"}, {"RegistryNumber": "E0399OZS9N", "NameOfSubstance": "Cyclic AMP"}, {"RegistryNumber": "H2D2X058MU", "NameOfSubstance": "Cyclic GMP"}, {"RegistryNumber": "X4W3ENH1CV", "NameOfSubstance": "Norepinephrine"}], "MeshHeadingList": [{"QualifierName": ["isolation & purification", "pharmacology"], "DescriptorName": "Adrenergic alpha-Antagonists"}, {"QualifierName": [], "DescriptorName": "Adrenergic beta-1 Receptor Antagonists"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug effects"], "DescriptorName": "Aorta, Thoracic"}, {"QualifierName": ["isolation & purification", "pharmacology"], "DescriptorName": "Berberine Alkaloids"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cyclic AMP"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cyclic GMP"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Cytokines"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Guinea Pigs"}, {"QualifierName": [], "DescriptorName": "In Vitro Techniques"}, {"QualifierName": ["metabolism"], "DescriptorName": "Inositol"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["drug effects"], "DescriptorName": "Muscle, Smooth"}, {"QualifierName": ["drug effects"], "DescriptorName": "Muscle, Smooth, Vascular"}, {"QualifierName": ["antagonists & inhibitors", "pharmacology"], "DescriptorName": "Norepinephrine"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["drug effects"], "DescriptorName": "Potassium Channels"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Inbred WKY"}, {"QualifierName": [], "DescriptorName": "Rats, Wistar"}, {"QualifierName": [], "DescriptorName": "Serotonin Antagonists"}, {"QualifierName": ["drug effects"], "DescriptorName": "Sodium Channels"}, {"QualifierName": ["drug effects"], "DescriptorName": "Trachea"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Pflugers Arch. 1981 Aug;391(2):85-100", "ArticleIdList": ["6270629"]}, {"Citation": "J Pharmacol Exp Ther. 1981 Jul;218(1):217-30", "ArticleIdList": ["6113280"]}, {"Citation": "Am J Physiol. 1985 Nov;249(5 Pt 2):H1056-60", "ArticleIdList": ["2998207"]}, {"Citation": "Pharmacol Rev. 1988 Jun;40(2):87-119", "ArticleIdList": ["2853370"]}, {"Citation": "J Physiol. 1955 Sep 28;129(3):568-82", "ArticleIdList": ["13264118"]}, {"Citation": "Br J Pharmacol. 1987 Jun;91(2):367-76", "ArticleIdList": ["2886169"]}, {"Citation": "Ann N Y Acad Sci. 1985;454:279-91", "ArticleIdList": ["3907467"]}, {"Citation": "J Clin Invest. 1986 Jul;78(1):1-5", "ArticleIdList": ["2873150"]}, {"Citation": "J Biol Chem. 1990 Jan 25;265(3):1268-73", "ArticleIdList": ["2153123"]}, {"Citation": "Br J Pharmacol. 1981 Nov;74(3):619-26", "ArticleIdList": ["6271321"]}, {"Citation": "Br J Pharmacol. 1976 Oct;58(2):211-21", "ArticleIdList": ["184872"]}, {"Citation": "Br J Pharmacol. 1984 Jan;81(1):16-8", "ArticleIdList": ["6704578"]}, {"Citation": "J Pharmacol Exp Ther. 1987 Sep;242(3):864-72", "ArticleIdList": ["2821228"]}, {"Citation": "J Physiol. 1985 Feb;359:485-501", "ArticleIdList": ["2582116"]}, {"Citation": "Biochem J. 1982 Sep 15;206(3):587-95", "ArticleIdList": ["7150264"]}, {"Citation": "Drugs. 1983 Apr;25(4):339-84", "ArticleIdList": ["6303744"]}, {"Citation": "Nature. 1981 May 28;291(5813):325-7", "ArticleIdList": ["7231552"]}, {"Citation": "Br J Pharmacol. 1986 Nov;89(3):525-32", "ArticleIdList": ["3026546"]}, {"Citation": "Eur J Pharmacol. 1987 Nov 24;144(1):7-14", "ArticleIdList": ["2830120"]}, {"Citation": "Annu Rev Physiol. 1986;48:307-20", "ArticleIdList": ["2871807"]}, {"Citation": "Pharmacol Rev. 1992 Sep;44(3):401-58", "ArticleIdList": ["1359584"]}, {"Citation": "Drugs. 1987 May;33(5):461-77", "ArticleIdList": ["2885169"]}, {"Citation": "J Pharmacol Exp Ther. 1987 Feb;240(2):535-41", "ArticleIdList": ["2879909"]}, {"Citation": "J Pharmacol Exp Ther. 1982 Jul;222(1):227-31", "ArticleIdList": ["6283070"]}, {"Citation": "J Biol Chem. 1951 Nov;193(1):265-75", "ArticleIdList": ["14907713"]}, {"Citation": "Life Sci. 1980 Oct 27;27(17):1525-40", "ArticleIdList": ["6255278"]}, {"Citation": "Nature. 1987 Jun 11-17;327(6122):524-6", "ArticleIdList": ["3495737"]}, {"Citation": "J Cyclic Nucleotide Res. 1979;5(3):211-24", "ArticleIdList": ["39089"]}, {"Citation": "J Physiol. 1982 May;326:475-93", "ArticleIdList": ["6286950"]}, {"Citation": "J Pharm Pharmacol. 1978 May;30(5):312-3", "ArticleIdList": ["26747"]}], "ReferenceList": []}], "History": [{"Year": "1993", "Month": "10", "Day": "1"}, {"Year": "1993", "Month": "10", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "1993", "Month": "10", "Day": "1", "Hour": "0", "Minute": "0"}, {"Year": "1994", "Month": "10", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["7902181", "PMC2175899", "10.1111/j.1476-5381.1993.tb13895.x"]}}]}